Cell and Gene Therapy (CGT) Infrastructure and Delivery Models Market Revenue and Forecast by 2033

16 Jul 2025

Share :

Table of Content

1. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market Revenue and Trends 2025 to 2033 2. What are the Major Factors Driving the Growth of the Market? 3. Segment Insights 4. Regional Insights 5. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market Coverage 6. Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market Key Players

Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market Revenue and Trends 2025 to 2033

The cell and gene therapy infrastructure & delivery models market is expanding through 2033, fueled by the shift toward decentralized manufacturing, cold-chain logistics, and clinic-based delivery models. The growth of the market is attributed to the increasing rates of clinical success of cell and gene therapies, as well as rising healthcare spending.

What are the Major Factors Driving the Growth of the Market?

The cell and gene therapy (CGT) infrastructure & delivery models market is experiencing significant growth, driven by several factors. Firstly, advancements in gene editing technologies (e.g., CRISPR) are leading to more precise and personalized therapies, which is a major driver. Secondly, the increasing incidence of chronic and genetic conditions, including cancer and rare inherited diseases, is creating demand. These emerging therapies offer promising long-term solutions. Finally, regulatory support, particularly with fast-tracked approvals from agencies like the FDA and EMA, is enabling quicker market access for new therapies. Moreover, rising government research and development (R&D) funding creates immense opportunities in the market.

Segment Insights

• By therapy type, the gene-modified cell therapy segment dominated the market in 2024. This is primarily due to the increased demand for CAR-T cell therapy, driven by its remarkable efficacy against complex cancers. The proven effectiveness of gene-modified therapies in treating a range of cancers makes them the preferred choice.
• By delivery mode, the centralized manufacturing & delivery segment led the market with a major share in 2024. This is primarily due to its improved manufacturing workflows, quality control, optimized cold-chain logistics, and a more efficient global delivery system.
• By infrastructure component, the manufacturing facilities segment held the largest portion of the market, driven by the increased demand for GMP-compliant facilities. The increased demand for viral vector manufacturing, the need for scalable manufacturing platforms, and complete end-to-end cold-chain logistics solutions further support segmental growth.
• By end-use, the biotech & pharmaceutical companies segment contributed the largest market share in 2024. This is primarily due to their increased involvement in the R&D of cell and gene therapies. The rising production of GMP-compliant CGT products further supports segmental growth.
• By the application stage, the clinical (phase I–III) segment held the dominant share of the market in 2024 due to increased demand for GMP-ready sites for clinical trials and scalable process validation requirements. The increased number of clinical trials for cell-based therapies also bolstered the segmental growth.
• By service provider, the contract development and manufacturing organizations (CDMOs) segment continues to dominate the market as biopharmaceutical companies are increasingly shifting toward outsourcing services. Outsourcing CGT manufacturing to CDMOs allows companies to save costs by eliminating the need to build in-house infrastructure, particularly for drug development.

Regional Insights

North America registered dominance in the cell and gene therapy (CGT) infrastructure & delivery models market by holding the largest share in 2024. The region benefits from a favorable regulatory landscape, an established biopharma ecosystem, and a network of GMP-certified facilities. There is a high adoption rate of CGT products, contributing to market expansion.

The market in Asia Pacific is expected to grow at the highest CAGR during the forecast period, driven by increasing government support, the development of healthcare infrastructure, and relatively low manufacturing costs. The rising prevalence of various diseases and increasing healthcare expenditure are likely to drive market growth.

Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market Coverage

Recent Development

• In July 2025, Cellular Origins, Cell and Gene Therapy (CGT) Catapult, and Resolution Therapeutics have formed a consortium to deliver a cell therapy manufacturing platform. The project commenced at the beginning of July and is scheduled to last for 20 months.
  (Source: https://www.bioprocessintl.com)

Cell and Gene Therapy (CGT) Infrastructure & Delivery Models Market Key Players

• Catalent Cell & Gene Therapy
• Lonza
• WuXi Advanced Therapies
• Thermo Fisher Scientific
• Charles River Laboratorie 
• BioLife Solutions
• TrakCel
• Vineti
• Cryoport Systems
• Be The Match BioTherapies
• Longevity BioImaging
• Ori Biotech
• Miltenyi Biotec
• Akron Biotech
• BioSpherix
• Cellino
• QuickSTAT
• Lonza Bioscience
• Marken
• SHL Medical

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6399

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344